I
Implantica
Implantable device treating gastroesophageal reflux disease.
About Implantica
Implantica is a medical technology group focused on developing and commercializing implantable devices to treat chronic health conditions. The company was officially founded in 2015 by Dr. Peter Forsell, a specialist surgeon from the Karolinska Institute. Dr. Forsell previously developed the Swedish Adjustable Gastric Band (SAGB) and co-founded Obtech Medical AG, which was sold to Johnson & Johnson. He invested over EUR 85 million from this prior success into Implantica to build out its technology and product pipeline. The company's lead product is RefluxStop™, a CE-marked implant for treating gastroesophageal reflux disease (GERD). Unlike other surgical treatments that encircle the food passageway, RefluxStop™ is designed to restore the natural anatomy by reconstructing the anti-reflux barrier, preventing the lower esophageal sphincter from moving into the thorax. This mechanism addresses the cause of reflux without being associated with common side effects like swallowing difficulties. The device received its CE mark in 2018, and as of September 2025, has been used to treat over 1,400 patients across Europe. The company is publicly listed on the Nasdaq First North Premier Growth Market in Stockholm, having raised SEK 1.265 billion in its September 2020 initial public offering. Implantica's business model centers on the sale of its RefluxStop™ device to hospitals and surgical centers, primarily in Europe, with a focus on establishing centers of excellence. The company operates in the gastrointestinal and urology segments of the MedTech market. Beyond its lead product, Implantica has developed a broad product pipeline based on two platform technologies. The first is a wireless energizing platform to power implants through the skin, and the second is the e-InVivo™ eHealth platform, which allows for remote monitoring, data collection, and control of treatments from inside the body. Future products in development include AppetiteControl™ for obesity and UriControl® for urinary incontinence.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2020
- Outcome tier
- Unicorn$1–10B valuation tier
Open roles
Implantica in its local ecosystem
The Implantica office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Implantica on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Implantica on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.



Implantica wins FDA approval for RefluxStop, opening the US market